Sensitivity analysis with follow-up beginning three years after baseline. by Karl Stattin (11836305)

Subjects:

Trend in PPI and H₂RA uses from 2010 to 2019 in Japan. by Nobutake Yamamichi (381131)

Subjects:

Risk of contracting any infection and pneumonia, being admitted to and intensive care unit and dying by smoking status. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis only considering the underlying cause of death. by Karl Stattin (11836305)

Subjects:

30-Day mortality after first diagnosis of pneumonia. by Karl Stattin (11836305)

Subjects:

Participant characteristics by smoking status in 1997: Never, former or current. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis adjusting for self-rated health. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis adjusting for body mass index. by Karl Stattin (11836305)

Subjects:

Risk of contracting any infection and pneumonia, being admitted to and intensive care unit and dying by pack years and years since smoking cessation. by Karl Stattin (11836305)

Subjects:

Sensitivity analysis with time from baseline as time scale. by Karl Stattin (11836305)

Subjects:

Cohort flowchart. by Karl Stattin (11836305)

Subjects:

Regression output from analyses of smoking status. by Karl Stattin (11836305)

Subjects:

Decreased production of highly reactive oxygen species production induced by complement-mediated phagocytosis in Rab27a-knockdown cells. by Tatsumi Kawakami (505540)

BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma. by Zahra Motahari (6814013)

The inhibitory activity of the most active compounds against Glo-I enzyme with less than 50 µM. Their supportive corresponding docking values on two different protocols are display... by MohammedBashar Al-Qazzan (22439236)

Elemental analysis shows a decreased N content in N stressed cells without a change in their C content. by Steve Dagenais Bellefeuille (654383)

SAA in a 50 year-old woman with HHT and severe liver involvement. by Jacques Sellier (8351355)

The total muscle and motor unit capacities for initial target forces of 15, 50 and 85% until total muscle capacity decreased to 15% MVC (ie. 85% muscle fatigue for each trial). by Jim R. Potvin (4062412)

Decreases in muscle size, muscle force, and TB mass in 3-mo Lmna^HSA-cko mice. by Lei Xiong (334812)

Lysine 50 of Tat regulates expression of C5, CRLF2, APBA1, and BDNF genes. by Loreto Carvallo (4167607)

“…<p>THP-1Tat-Flag and THP-1Tat K50ATat-Flag cell lines (generated from independent experiments described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0179882#pone.0179882.g005" target="_blank">Fig 5</a>) were differentiated to macrophages with PMA for 24 and 48 hours. …”